Restoration of regulated insulin secretion is the ultimate goal of therapy for type 1 diabetes. Here, we show that, unexpectedly, somatic ablation of Foxo1 in Neurog3 + enteroendocrine progenitor cells gives rise to gut insulin-positive (Ins + ) cells that express markers of mature b cells and secrete bioactive insulin as well as C-peptide in response to glucose and sulfonylureas. Lineage tracing experiments showed that gut Ins + cells arise cell autonomously from Foxo1-deficient cells. Inducible Foxo1 ablation in adult mice also resulted in the generation of gut Ins + cells. Following ablation by the b-cell toxin streptozotocin, gut Ins + cells regenerate and produce insulin, reversing hyperglycemia in mice. The data indicate that Neurog3 + enteroendocrine progenitors require active Foxo1 to prevent differentiation into Ins + cells. Foxo1 ablation in gut epithelium may provide an approach to restore insulin production in type 1 diabetes.
A r t i c l e s A longstanding goal of regenerative medicine is the identification of genetic, cellular and biochemical pathways governing the generation of insulin-producing β cells, with a view toward enlisting them in ongoing cellular replacement efforts in individuals with type 1 diabetes 1, 2 . The process by which primitive endodermal precursors adopt an endocrine fate has been examined in detail 3 . A key step seems to be the formation of Neurog3-expressing (Neurog3 +) cells that go on to differentiate into all known pancreatic islet cell types [4] [5] [6] . Of note, Neurog3 + endocrine progenitors are not restricted to the pancreas but are found in the stomach and intestine, where they give rise to most cells in the enteroendocrine system, the largest endocrine organ in the body 7, 8 .
Despite their common endodermal origin, pancreatic and gut Neurog3 + endocrine progenitors share few if any properties, giving rise to cell types that produce distinct peptide hormones and have remarkably different developmental fates and lifespans 9 . Pancreatic endocrine progenitors are formed during embryonic development and do not arise again in the adult organ 10 , except under special circumstances 11 . Enteroendocrine progenitors instead continually arise from gut stem cells and contribute to the repopulation of the highturnover enteroendocrine population 8 . The distinct features of these two cell populations dovetail with the classical theory of positional specification, whereby partly committed progenitor cells acquire position-dependent properties that dictate specific fates 12 . It is unclear how gut Neurog3 + progenitors are restricted to the enteroendocrine versus the pancreatic endocrine fate. Understanding this mechanism would allow investigators to explore the use of gut epithelium as a source for cell replacement therapy in insulin-dependent diabetes, given the self-renewing nature of this tissue.
Foxo transcription factors integrate hormonal and nutrient cues with the cell transcriptional response to regulate diverse cellular processes 13 . In addition to their metabolic functions, Foxo proteins inhibit terminal differentiation in multiple cell types [14] [15] [16] . In myoblasts, Foxo1 can affect cell fate decisions in a Notch-dependent manner, leading to the generation of different muscle fiber types 17 . In the pancreas, Foxo1 has an important role in regulating endocrine cell mass [18] [19] [20] and β-cell responses to oxidative stress 21, 22 . Of note, Foxo1 is coexpressed with Neurog3 in embryonic pancreas, but Foxo1 ablation does not affect the generation of different pancreatic endocrine cell types 18 . In cultures of human fetal pancreatic epithelium, FOXO1 knockdown increases the number of NEUROG3 + cells 23 . In contrast, virtually nothing is known about the functional properties of Foxo1expressing cells in the gut. In this study, we use a combination of genetic and cellular approaches to characterize these cells.
RESULTS

Foxo1 ablation expands Neurog3 + enteric progenitors
Foxo1 is expressed in gut epithelial cells, including most Neurog3 + enteroendocrine progenitors (Supplementary Fig. 1a ). To investigate its role in this cell type, we generated mice with somatic deletion of Foxo1 in Neurog3 + cells 8 (Neurog3-Cre-driven Foxo1 knockouts; NKO). To assess Cre-mediated recombination, we intercrossed NKO and Neurog3-Gfp transgenic mice (Supplementary Fig. 1b) . In control studies, we determined that GFP immunoreactivity colocalized with endogenous Neurog3 immunoreactivity ( Supplementary  Fig. 1c ). In NKO mice, Foxo1 was no longer detectable in GFPlabeled cells ( Supplementary Fig. 1b) , and Foxo1 mRNA levels were decreased by >80% in flow-sorted cells from Neurog3-Gfp animals, A r t i c l e s indicating that the deletion occurred efficiently ( Supplementary  Fig. 1d ). Similar to findings in human cells following FOXO1 knockdown 23 , Foxo1 ablation resulted in a tenfold increase in the number of Neurog3 + cells ( Fig. 1a) , as demonstrated by (i) immunohistochemistry with antibody to Neurog3, (ii) lineage tracing studies with either Neurog3-Gfp transgenics 10 or Neurog3-Gfp knock-in mice 7 , (iii) flow cytometry analysis of GFP + cells derived from NKO; Neurog3-Gfp double transgenic mice ( Fig. 1b and Supplementary  Fig. 1b-g) and (iv) Neurog3 mRNA measurements in flow-sorted GFP + cells (Fig. 1c) . The increase of Neurog3 + cells was associated with a similar increase in cells expressing chromogranin A (ChgA) ( Fig. 1d,e ), a marker of endocrine cell differentiation that is temporally expressed after Neurog3, indicating that Foxo1 ablation leads to the expansion of gut Neurog3 + progenitors and their daughter cells 9 . These data were substantiated by immunohistochemistry with antibody against Neurog3 in the large intestine, as well as by immunofluorescence with antibody against GFP in the adult gut from Neurog3-Gfp transgenic and knock-in mice ( Supplementary  Fig. 1e-h ). In addition, it is possible that some epithelial progenitors express low levels of Neurog3 that escape detection by GFP or immunohistochemistry, although they could still produce enough Cre to inactivate Foxo1, leading to further activation of Neurog3.
Neurog3 is physiologically repressed by Notch signaling via Hes1 (ref. 24) . The coordinated expansion of Neurog3 + and ChgA + cells in NKO mice phenocopies loss of Notch function in Hes1 knockouts 5, 25 . As Foxo1 regulates Hes1 in cooperation with Notch 17 , we investigated whether Foxo1 ablation in Neurog3 + progenitors affected Hes1 expression. Indeed, Hes1 protein ( Fig. 1f ) and mRNA levels ( Fig. 1g) were substantially decreased, as were mRNA levels of the Hes-related gene HesR1, in gut epithelial cells with Foxo1 ablation, whereas HeyL levels were unchanged (Fig. 1g) . These data indicate that Foxo1 ablation inhibits Hes1 expression.
Gut insulin-producing cells in NKO mice
Hes1 restricts the endocrine plasticity of Neurog3 + progenitors during endodermal development 25, 26 . Therefore, we surveyed the pancreas and intestines of newborn and adult mice by immunohistochemistry with antibodies against enteric and pancreatic islet hormones. In neonatal NKO gut, we made the unexpected finding of pancreatic hormone-producing cells, including insulin-immunoreactive cells (Ins + ) ( Fig. 2a and Supplementary Fig. 2a ) and, at lower frequencies, cells immunoreactive with pancreatic glucagon (Gcg + ) or pancreatic polypeptide (Ppy + ) ( Supplementary Fig. 2a ). We also observed Ins + cells throughout the gut of adult mice, primarily in the distal ileum and colon ( Supplementary Fig. 2b,c) , albeit with lower frequency than in newborns, possibly reflecting the relative expansion of gut epithelium relative to enteroendocrine lineages 27 . In addition, we detected Ins1 and Ins2 mRNA ( Fig. 2b) in the small and large intestine but not in other Neurog3-expressing tissues, such as brain, hypothalamus, stomach and testis ( Supplementary Fig. 2d ).
To investigate the origin of Ins + cells and provide independent evidence for their identity, we generated additional genetic models in mice. First, we ablated Foxo1 in duodenal epithelial precursors-the forerunners of Neurog3 + cells-using Pdx1-Cre 28 (Pdx1-Cre-driven Foxo1 knockouts; PKO). Crosses of PKO mice with Neurog3-Gfp reporter mice confirmed Foxo1 ablation ( Supplementary Fig. 2e ). Similar to NKO mice, PKO mice had Ins + cells in the duodenum and a marked increase in Neurog3 + -GFP + cells ( Supplementary Fig. 2f,g) . These data are consistent with the hypothesis that Foxo1 inhibition in duodenal epithelium precursors is sufficient to generate Ins + cells.
Next, we generated an Ins2-Gfp knock-in allele by gene targeting to provide a sensitive and specific readout of endogenous Ins2 transcription. When we introduced the Ins2-Gfp allele into NKO mice, we readily detected Ins2-Gfp + cells in the gut of mutant mice but not in wild-type littermates. In contrast, we detected Ins2 + -GFP expression in pancreatic islets of both genotypes ( Supplementary Fig. 2h,i) . Double immunohistochemistry with antibodies to either insulin or C-peptide and GFP confirmed that GFP + cells were Ins + cells ( Fig. 2c and Supplementary Fig. 2j ).
Gut Ins + cells express markers of insulin-producing cells
We analyzed gut Ins + cells by immunohistochemistry. In addition to markers shared in common between insulin-producing and enteroendocrine cells, such as synaptophysin (Syp) ( Fig. 2d) , glucokinase (Gck) and prohormone convertase-1 (Pcsk1) ( Supplementary Fig. 2k,l) , Ins + cells expressed markers that are highly enriched in pancreatic β cells but that are restricted or absent in the gut, such as prohormone convertase-2 (Pcsk2) 29 and C-peptide, the enzymatic byproduct of proinsulin processing ( Fig. 2d) . Furthermore, coimmunostaining revealed that Ins + cells were distinct from cells producing pancreatic glucagon, Glp1, somatostatin and Ppy, indicating that they are not mixed-lineage endocrine cells ( Fig. 2e and Supplementary Fig. 2a ). Quantitative analyses showed A r t i c l e s that gut Ins + cells arise slightly more frequently than L cells (Fig. 2f ). The morphology of Ins + cells is conducive to hormone release into the circulation, with narrow apical tips facing the gut lumen and a wide basal membrane facing blood vessels ( Fig. 2d) .
To rule out the possibility that gut Ins + cells arose as a consequence of genetic reprogramming of enteroendocrine precursors caused by Foxo1 ablation during fetal development, we inactivated Foxo1 in enteroendocrine progenitors of adult mice using an inducible binary transgenic system. To this end, we intercrossed mice with loxP-flanked alleles of Foxo1 (Foxo1 fl/fl ) with mice with tamoxifen-inducible Cre expression (CreER T ) from the Neurog3 locus 30 to generate Neurog3 CreERT knockout mice. We injected 10-week-old mice with tamoxifen or saline and surveyed the intestines after 2 weeks for the appearance of Ins + cells. Tamoxifen-exposed Neurog3 CreERT animals showed Ins + -Pcsk2 + -C-peptide + gut cells, whereas wild-type controls did not ( Fig. 2g) . These data show that Neurog3 + progenitors require active Foxo1 to repress the gut Ins + fate during intestinal homeostasis in adult animals.
Glucose-dependent release and bioactivity of enteric insulin
Regulated insulin secretion is a critical feature of pancreatic β cells that has proved difficult to replicate in embryonic stem cell-derived insulinproducing cells 2 . To determine whether gut Ins + cells are functionally competent to secrete insulin, we performed ex vivo assays of insulin secretion in response to glucose and ATP-sensitive potassium (K ATP ) channel modulators, using the pancreatic islet vital dye dithizone (DTZ) 31 to select gut segments enriched in Ins + cells from NKO mice and anatomically matched segments from wild-type controls. NKO intestines released insulin and C-peptide in response to glucose in a dose-dependent manner. The sulfonylurea glibenclamide (a K ATP channel blocker) augmented glucose-induced insulin release, whereas the K ATP channel opener diazoxide blunted it ( Fig. 3a,b) . These findings are consistent with immunohistochemical analyses indicating that Ins + cells possess the relevant sensing proteins Gck (Fig. 2d) , sulfonylurea receptor 1 (Sur1; encoded by Abcc8) and glucose transporter 2 (Glut2; encoded by Scl2a2) (Supplementary Fig. 3a,b) . Thus, functional and histochemical findings support the conclusion that gut Ins + cells are capable of regulated insulin secretion in response to glucose and K ATP channel modulators.
To examine whether intestinal insulin is bioactive, we prepared acid-ethanol extracts from NKO gut, as well as from the gut, pancreas and liver of wild-type mice, and injected them into newborn mice. Extracts from newborn NKO intestine lowered blood glucose by ~20%, similar to the reduction achieved by injecting animals with recombinant human insulin (2 U/kg) or with pancreas extracts from age-matched wild-type mice. In contrast, extracts from wild-type intestines or liver had no effect (Fig. 3c) . The ability of NKO gut extracts to lower blood glucose was preempted by the addition of an insulin-neutralizing antibody, as was the activity of pancreatic extracts from wild-type mice and recombinant insulin, whereas incubating NKO gut extracts with isotype-matched control IgG had no effect on their ability to lower glycemia ( Fig. 3c) , indicating that the hypoglycemic effect is due to insulin and not to other factors in the NKO gut extracts. These results show that gut-derived insulin is bioactive.
Regeneration of gut Ins + cells following streptozotocin ablation
Unlike pancreatic endocrine cells, enteroendocrine cells arise from Neurog3 + progenitors throughout life 8 . Therefore, gut Ins + cells should have greater regenerative capabilities than islet β cells in a toxin-induced diabetes model. Streptozotocin (STZ) administration to NKO and wild-type mice resulted in hyperglycemia ( Fig. 4a) . Glucose levels in wild-type mice were kept at ~500 mg/dl by daily insulin administration for 28 d, whereas, in contrast, we treated NKO mice with insulin from day 3 to day 7. However, the glucose levels in NKO mice began to spontaneously decrease 9 d after STZ administration and stabilized at ~250 mg/dl in the fed state, consistent with the restoration of insulin production ( Fig. 4a) . Following insulin withdrawal, all wild-type mice died, whereas 75% of NKO mice survived until the end of the experiments (Fig. 4b) . Moreover, STZ-treated d WT
Ins Pcsk2
Ins C-pep.
Ins Gck
Ins Syp A r t i c l e s NKO mice showed near-normal oral glucose tolerance (Fig. 4c) . The improvement could not be ascribed to pancreatic β-cell regeneration, as pancreatic insulin content at the end of the experiment was at the lower limits of detection of the assay (<1% of the insulin level in vehicle-treated controls) ( Fig. 4d) . We examined gut specimens obtained 3 d after STZ administration, and Ins + cells were undetectable in either genotype (Supplementary Fig. 4a ). However, at day 28 after STZ exposure, gut Ins + cells were present in NKO gut at a higher frequency than in mice before STZ treatment (10.5% versus 4.5% of total Neurog3 + cells; P < 0.001) ( Fig. 4e ) and expressed markers of mature β cells, including Pcsk2 and C-peptide ( Supplementary Fig. 4a,b ), suggesting that their functional properties were intact. Moreover, we detected insulin, as well as C-peptide 2, in fasted and fed STZ-treated NKO mice using a murine-specific ELISA, whereas in wild-type mice, values were at the lower limit of detection ( Supplementary Fig. 4c-h) .
There was no immunohistochemical evidence of pancreatic β-cell regeneration in NKO mice nor of Ins + cells in wild-type gut or pancreas at any stage following STZ exposure (Supplementary Fig. 4a ).
The sensitivity of gut Ins + cells to STZ ablation provides additional evidence that these cells are similar to pancreatic β cells 32 .
As Neurog3 is also expressed in the brain 33 , we sought to determine whether there was a contribution from this organ to the observed survival of STZ-exposed NKO mice. To this end, we administered STZ to mice with pan-neuronal Foxo1 ablation (Syn-Cre; Foxo1f l/fl known as brain knockouts; BKO) (H. Ren and D.A., unpublished observation) and their wild-type littermates and treated them with insulin from day 3 to day 7. In either genotype, we failed to observe rescue of diabetes ( Supplementary Fig. 4i) , effectively ruling out a contribution from neuronal Foxo1 ablation to this phenotype.
Derepression of the b-cell program in NKO gut
To probe the identity of gut Ins + cells, we surveyed expression of pancreatic and intestinal markers. Immunohistochemistry showed that gut Ins + cells express epithelial markers, such as E-cadherin, but not mesenchymal markers, such as Cd45R, laminin or smooth muscle actin (Sma) ( Fig. 5a and Supplementary Fig. 5a-c) . This finding indicates that these cells do not arise in response to an epithelial-tomesenchymal transition 34 . Moreover, gut Ins + cells express the insulin gene transcription factor MafA, and MafA + cells also express pancreatic β-cell transcription factors Nkx6.1 and Pdx1 (Fig. 5b-d and Supplementary Fig. 5d ). In addition, consistent with the presence of cells immunoreactive with pancreatic glucagon ( Fig. 2e) , we detected immunostaining with the α-cell transcription factor MafB, as well as increased levels of mRNA encoding αand β-cell transcription factors Pdx1, MafA, Nkx6.1, Nkx2.2, Pax4, Arx and MafB but not NeuroD1 or Pax6 in gut segments enriched with Ins + cells ( Supplementary Fig. 5e,f ). Development of enteroendocrine L cells is dependent on Pax6 (ref. 9) , whereas that of cholecystokinin (Cck) cells is dependent on NeuroD1 (ref. 35) . Consistent with the normal expression levels of Pax6 and NeuroD1, morphometric analysis of immunostaining data showed that the number of L cells and of Cck-and serotonin-producing cells was unchanged in NKO mice (Fig. 2e,f and  Supplementary Fig. 5g ). The transcription factor Cdx2 is required for gut endoderm differentiation 36 npg A r t i c l e s with expanded Nkx 2.2 and Nkx 6.1 neuronal domains 41 . In addition, Aes is an endogenous repressor of Notch signaling and Hes1 expression in colon 42 . By immunohistochemistry, we localized Aes expression specifically to Ins + cells (Fig. 6c) . Accordingly, lineage tracing experiments indicated that GFP + cells in NKO; Rosa26-eGfp mice were decorated by Aes antibodies (Fig. 6d) , showing that Foxo1 ablation promotes Aes expression in a cellautonomous fashion. Next, we recapitulated gut Ins + cell differentiation ex vivo. We isolated intestinal crypts containing Neurog3 + progenitors from mice carrying the Ins2-Gfp reporter allele and subjected them to treatment with Wnt3a and fibroblast growth factor 4 (Fgf4) to attempt to mimic gene expression findings in PCR arrays from NKO mice (Supplementary Fig. 6c ). Under these conditions, we observed green fluorescent (Ins2 + -GFP + ) cells in primary cultures from NKO but not wild-type mice ( Fig. 6e and Supplementary Fig. 6d ).
Using the Wnt3a-Fgf4 induction protocol for primary crypt cultures, we investigated the requirements for Foxo1, Notch and/or Wnt signaling and Aes in the generation of Ins + cells. Cellular transduction with a constitutively active Foxo1 adenovirus (ADA) confers Foxo1 gain of function 15 and would thus be predicted to prevent the generation of Ins2 + -GFP + cells in cells from NKO mice. Indeed, following expression of Foxo1 ADA, the number of Ins2 + -GFP + cells decreased, whereas the control (LacZ) adenovirus had no effect (Fig. 6f) . Foxo1 is known to interact with Notch through its coregulatory functions, independent of DNA binding 17 . Accordingly, one could further predict that transduction with a constitutively nuclear, DNA binding-deficient Foxo1 (DBD ADA) would also decrease the number of Ins2 + -GFP + cells, a result which we also in fact observed (Fig. 6f) . In contrast, isolated Notch inhibition alone, with Compound E, or isolated Wnt activation, with the small molecule sc-222416, did not phenocopy Foxo1 inhibition and failed to give rise to Ins2 + -GFP + cells, consistent with the hypothesis that Foxo1 ablation brings about the phenotype by virtue of its combined effects on Notch and Wnt signaling. Finally, we examined the requirement for Aes in this process. When we treated primary crypt cultures with small interfering RNA (siRNA) to Aes, the number of Ins2 + -GFP + cells decreased from 0.14% to 0.03% of the total (Fig. 6f) , whereas a control siRNA had no effect. These findings were accompanied by the expected changes in Aes expression ( Supplementary Fig. 6e) . The data suggest that Aes mediates the effects of Foxo1 ablation and that its ectopic expression is necessary for the appearance of Ins2 + -GFP + cells. in loss of intestinal identity in a subpopulation of cells that become transcommitted to the pancreatic fate 25 . In contrast, gut Ins + cells in NKO mice were immunoreactive to Cdx2, indicating that they retain intestinal properties (Fig. 5e) . Taken together, these findings provide further evidence that Foxo1 ablation in NKO mice causes derepression of the β-cell (and pancreatic endocrine) program rather than transdifferentiation of gut epithelium into the pancreatic fate.
Altered Notch and Wnt signaling in gut Ins + cells
To distinguish whether Ins + cells arise from cell-autonomous mechanisms, we performed genetic lineage tracing experiments. We generated NKO mice bearing a Rosa26-eGfp reporter allele to label Neurog3-Cre-active cells and their daughter cells in adult intestines. In the pancreas, all islet cells were GFP + (Fig. 6a) . In the NKO gut, Ins + cells were GFP + , as were C-peptide + cells (Fig. 6a) , indicating that insulin expression occurred in cells that had undergone Cre-mediated recombination. This conclusion was upheld by studies in STZ-treated NKO; Rosa26-eGfp mice. Similar to the state before STZ administration, Ins + cells arising after STZ treatment activated endogenous Pcsk2 expression in a cell-autonomous manner (Supplementary Fig. 6a ).
Notch and Wnt pathways have critical roles in intestinal epithelial lineage specification 37 and interact with Foxo1 (refs. 17, 38) . To understand whether Foxo1 ablation affected these pathways, we used low-density array profiling of gut epithelial cell mRNA to identify gene expression changes associated with the appearance of Ins + cells in NKO mice. In isolated epithelial cells from DTZ-enriched NKO gut, we confirmed the substantial downregulation (700%) of Hes1 observed by immunohistochemistry and quantitative PCR (qPCR) (Fig. 1e,f) , thus validating the experimental approach. Whereas some of the Notch pathway-specific genes were downregulated, several transcripts shared in common by Notch and Wnt signaling were upregulated in the Notch and Wnt arrays. Among them, we detected a substantial (>300-fold) increase in the levels of transcripts from the Aes groucho-related gene (encoding N-terminal enhancer of split; also known as Tle5 or Grg5), and we confirmed this change by qPCR analysis 37 (Fig. 6b and Supplementary Fig. 6b,c) . We also saw a greater than threefold increases in Fzd1, Fzd2, Fzd3 and Fzd4 levels (Supplementary Fig. 6c) . In contrast to the Notch array, the Wnt array showed upregulation of Wnt ligands, receptors and transcription factors (Supplementary Fig. 6c ). Expression of the Ctbp1 gene (encoding the corepressor of Polycomb 2-mediated transcription, Cterminal-binding protein 1) was decreased to 0.0008% of control levels (Supplementary Fig. 6c ), a finding that might be expected to increase cellular plasticity 39 . These data suggest that Foxo1 ablation activates Wnt signaling thereby derepressing enteroendocrine differentiation pathways, supporting the notion that Foxo1 inhibits Wnt signaling 16, 38 .
To mechanistically link gene expression and cellular differentiation data, we investigated the role of Aes in more detail. Aes is expressed in the pancreas 40 , and ectopic Aes expression is associated npg DISCUSSION In this work, we show that fetal and adult ablation of Foxo1 in enteroendocrine progenitors gives rise to cells with lineage and functional features of insulin-producing, glucose-responsive cells. Functional ex vivo data show that gut Ins + cells release insulin in a glucose-regulated manner and are inhibitable by diazoxide, allaying fears of unchecked insulin release that have plagued cellular replacement approaches to type 1 diabetes. As both pancreatic β and enteroendocrine cells physiologically express Glut2, Gck and Sur1 (refs. 43,44) , the ability of gut Ins + cells to secrete insulin might reflect shared glucose-sensing properties between these cell types. There are, however, important differences between Ins + cells described in this study and enteroendocrine cells, as (i) Foxo1 ablation increases expression of β-cell transcription factors Pdx1, Neurog3, MafA and Nkx6.1 and of the pancreatic endocrine cell-specific terminal differentiation marker Pcsk2; (ii) the observation that Ins + cells in NKO mice express the Ins2-Gfp knock-in allele provides evidence of activation of a pancreatic β−cell-like developmental pathway sufficient for glucose-stimulated insulin secretion; and, (iii) finally, we provide in vivo evidence that intestinal insulin is bioactive.
A critical distinguishing feature of gut Ins + cells from other cell types that have been shown to give rise to Ins + cells is that gut Ins + cells can regenerate rapidly following STZ-mediated ablation, unlike embryonic stem cell-derived insulin-producing cells 2, 45 . As Ins + gut cells in untreated NKO mice and in mice after STZ administration express similar markers of mature β cells (Pcsk2) and active Wnt signaling (Aes), we speculate that they arise from similar developmental programs.
The morphology of gut Ins + cells (Fig. 2d) is consistent with the possibility that they secrete insulin in response to bloodborne rather than gut lumenal cues. Gut Ins + cells are not arrayed into islet-like structures, but neither are other enteroendocrine cells, possibly reflecting spatial and temporal constraints.
Lineage tracing data indicate that Ins + cells arise in a cell-autonomous manner from Foxo1-deficient Neurog3 + progenitors, as do Gcg + and Ppy + cells, albeit at commensurately lower frequencies, suggesting that the entire pancreatic endocrine lineage is derepressed by Foxo1 ablation. This property is loosely reminiscent of the ability of other forkhead proteins to repress mesenchymal fate in neural crest progenitors 46 or the testis-specific enhancer Sox9 in ovaries 47 . This finding suggests that, in normal development and intestinal homeostasis, Foxo1 acts as a cell-autonomous suppressor of the pancreatic endocrine fate in Neurog3 + progenitors (Supplementary Fig. 7) .
We provide evidence that Foxo1 ablation converts gut Neurog3 + progenitors into progenitors of gut and pancreatic endocrine lineages through altered Notch (decreased Hes1) and Wnt (increased Aes) signaling pathways, both of which have been shown to regulate gut and pancreatic differentiation and to interact with Foxo 17, 38 . The ability of Foxo1 ablation to steer enteroendocrine Neurog3 + progenitors toward the pancreatic endocrine lineage cannot be ascribed solely to Neurog3 gain of function, because only a fraction of Neurog3 + cells become Ins + . Moreover, Neurog3 overexpression is not sufficient to yield Ins + cells 48 .
In a broader context, the plasticity of enteroendocrine cells, as highlighted by our findings, could have an important role in the metabolic functions of the gut 49 . Furthermore, the ability of NKO mice to regenerate gut Ins + cells following STZ treatment suggests that pharmacological or RNA interference-based Foxo1 inhibition in the gut will improve prospects of cell-based therapies to replace insulin administration in type 1 diabetes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METHODS
Antibodies and immunohistochemistry. We performed tissue fixation and processing for immunohistochemistry as described 19 . We used rabbit primary antibodies to Foxo1 (sc-11350 and Cell Signaling #2880), Pcsk1 (sc-33813), glucokinase (sc-7908, Santa Cruz), Pdx1 (gift from C. Wright, Vanderbilt University), cholecystokinin (ARP33849_P050, Aviva System Biology), laminin (Ab 11575, Abcam), serotonin (NB120-16007, Novus Biologicals), C-peptide (H-035-03), glucagon (H-028-02), Glp-1 (G-028-13), pancreatic polypeptide (H-054-07 by Phoenix Peptide), GFP (A11122, Invitrogen), chromograninA (AB9254), Glut2 (AB1342), Pcsk2 (AB15610, Millipore), MafA and MafB (IHC-00352 and IHC-00351, Bethyl Laboratories); guinea pig primary antibodies to insulin (A0564, Dako); mouse primary antibodies to glucagon (G2654), Neurog3 (SAB3300089), Actin, α-smooth muscle (A2547 Sigma), Cd45R (554879 BD Pharmigen), E-cadherin (610181, BD Bioscience), Cdx2 (MU392A-UC, Biogenex), Neurog3 (F25A1B3, Developmental Studies Hybridoma Bank) and synaptophysin (M0776 Dako); and goat primary antibodies to GFP (600-141-21, Rockland), Nkx6.1 (sc-15030), Sur1 (sc-5789), TLE5/Aes (sc-69045) and Neurog3 (sc-13793, Santa Cruz). For Hes1 staining, we used rat primary antibody to HES-1 (MBL International) and the TSA-HRP Amplification kit (Invitrogen) as described 50 . We used FITC, Cy3conjugated (Jackson ImmunoResearch Laboratories) and Alexa-conjugated donkey secondary antibodies (Molecular Probes Inc) or peroxidase staining as described 50 . We stained nuclei with DAPI or DRAQ5 (Cell Signaling) and acquired and analyzed images as described 19 . We obtained images of immunofluorescent colocalization using confocal microscopy (Zeiss LSM 510). Gut morphometric analysis was sampled from four sections 150 µM apart, and we counted at least 1,000 ChgA + cells per mouse.
Animals. Pdx1-Cre 28 , Neurog3-Cre 8 , Rosa26-eGfp, Neurog3-Gfp 10 and Neurog3 CreERT (ref. 30 ) mice have been described. We used 4-hydroxytamoxifen (4HT; Sigma) to activate recombination by Cre ERT . We intercrossed these mice with Foxo1 fl/+ mice 51 to generate Neurog3-Cre; Foxo1 fl/fl (NKO) and Pdx1-Cre; Foxo1 fl/fl (PKO) mice. To generate Ins2-Gfp knock-in mice, we modified the RP22-342 BAC clone (CHORI) by recombineering to replace the Ins2 coding sequence with Gfp. We transfected recombinant clones into embryonic stem cells and selected homologous recombinants by Southern blotting. We generated germline chimeras as described previously 52 .
Physiological studies. We induced diabetes by intraperitoneal injection of streptozotocin (325 mg/kg) in 8-to 10-month-old mice. Only mice with blood glucose levels higher than 500 mg/dl at day 3 after STZ administration were used for further experiments. We treated control mice with daily injections of 2-4 U of NPH-insulin (Eli Lilly). We measured fed glucose and insulin and C-peptide 2 by ELISA (Millipore) as described 52 .
Insulin bioassay. We prepared acid-ethanol extracts from neonatal (postnatal day (P) 3) gut, liver and pancreas 53 . We mixed tissue extract or recombinant human insulin (Humulin R, Eli Lilly) in acid-ethanol solution with either insulin neutralizing antibody (MA1-27288 Thermo Scientific) or isotypematched mouse IgG1 (14-4714-82 Ebiosciences) for subcutaneous injections of 2 U/kg body weight. We measured glucose immediately before and 5 min after injection.
Insulin secretion and content. We stained adult intestine in medium containing 0.12 mM dithizone 31 and selected 5-inch-long DTZ + fragments from NKO mice or anatomically matched fragments from control, wild-type mice.
We made en face preparations of the intestines and incubated them in Krebs Ringer buffer (Sigma) supplemented with glucose at various concentrations, diazoxide (Sigma) or glibenclamide (Tocris) for 1 h. At the end of the incubation, we measured insulin and C-peptide 2 content in the medium by ELISA (Millipore). Collagenase-purified pancreatic islets from 14-week-old wild-type mice served as controls 18 . Pancreatic insulin content was extracted with acid-ethanol solution 53 and measured by ELISA.
Isolation of gut epithelial cells. We dissected intestines en face, washed them with PBS (with Mg 2+ and Ca 2+ ), minced them into 5-to 10-mm-long pieces and incubated them in 20 mM EDTA at 37 °C, after which they were vigorously resuspended in cold PBS. We then collected the released epithelial cells for secretion and RNA assays. We carried out single-cell isolation of gut epithelium for FACS analysis as described, except that we included villi fractions 27 .
Primary gut culture. We seeded cells in a 1:5 dilution of Matrigel (BD Bioscience) 54 and incubated them overnight in basal medium modified to include antibody to mouse epidermal growth factor (mEGF; 20 ng/ml), insulin from bovine pancreas and hydrocortisone-21-hemisuccinate sodium salt (150 nM) (all from Sigma), N2 and B27 supplements (R&D Systems) and 2% FCS (Hyclone, Thermo Scientific). Cultures were then transferred to either basal or advanced medium that included Chir99021 (6 µM) and LDN-193189 (Stemgent) for 4 d with the following recombinant proteins alone or in combination: m-Wnt3a, m-Wnt5b, R-spondin, Noggin and Fgf4 (200 ng/ml). We prepared SMARTpool Aes and control siRNA as indicated by the manufacturer's protocol (Themo Scientific). We carried out adenoviral transduction as described 17 
Statistical analysis.
We analyzed data using the Student's t test, and data are presented as mean ± s.e.m.
